NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP...

Area of Science:

• Neuroscience
• Pharmacology
• Alzheimer's Disease Research

Background:

• Microdose lithium has shown promise in reducing Alzheimer's disease (AD) risk by targeting AD pathology mechanisms.
• Previous studies indicated NP03, a novel microdose lithium formulation, has disease-modifying effects in preclinical AD models at pre-plaque stages.
• The current research investigates if NP03's benefits extend to early amyloid-beta (Aβ) post-plaque stages.

Purpose of the Study:

• To determine the efficacy of microdose lithium NP03 in the early Aβ post-plaque stages of Alzheimer's disease.
• To assess NP03's impact on cognitive function, specifically remote working memory.
• To evaluate NP03's effects on amyloid pathology, neuroinflammation, and oxidative stress markers.

Main Methods:

• Administration of NP03 to McGill-R-Thy1-APP transgenic rats for 12 weeks, covering the transition to plaque deposition.
• Assessment of working memory using the novel object recognition task.
• Measurement of Aβ levels, pro-inflammatory mediators, thioflavin-S positive plaques, VAChT bouton density, CXCL1, IL-6, and 4-HNE via electrochemiluminescence and immunohistochemistry.

Main Results:

• NP03 administration rescued object recognition deficits in early post-plaque stages.
• Treatment with NP03 reduced cholinergic bouton loss in the hippocampus.
• NP03 decreased soluble and insoluble cortical Aβ42 levels, reduced hippocampal Aβ plaque counts, and lowered markers of neuroinflammation and oxidative stress.

Conclusions:

• Microdose lithium NP03 demonstrates therapeutic efficacy even after the onset of amyloid plaque deposition in an AD model.
• NP03 treatment positively impacts cognitive function and key pathological hallmarks of Alzheimer's disease.
• These findings suggest NP03 is a potential therapeutic agent for later stages of amyloid pathology.